Combinations of drugs are increasingly being used on pharmacologic grounds. Examples of the use of these combinations include cancer chemo therapy treatment and hypertension treatment.1"3 The goal of using two or more drugs instead of one is to achieve greater efficacy with the same or fewer adverse effects or equal efficacy with fewer adverse effects. 4, 5 In pharmacologic terms this would signify supraadditive efficacy with additive or infraadditive toxicity and additive efficacy with infraadditive tox icity, respectively. Consequently, numerous clinical trials are being undertaken to compare combination regimens with their individual constituents.
However, the total drug load (i.e., the amount of drug exposure for a certain indication) is a neglected factor in many of these trials. When differences in effects are found in these trials, they are attributed to the pharmacodynamic properties of the therapeu tic regimens instead of to a possible difference in drug load between the groups. However, the drug loads of two regimens should be equal before con clusions are reached on differences of intrinsic efficacy or toxicity.
Many examples of neglecting drug load can be found in the literature. MacKay et al.6 evaluated the effects of 50 mg losartan alone, 12.5 mg hy drochlorothiazide alone, a combination of 50 mg losartan and 6.25 mg hydrochlorothiazide, and a combination of 50 mg losartan and 12.5 mg hy drochlorothiazide for essential hypertension and 592 concluded that the combination of 50 mg losartan and 12.5 mg hydrochlorothiazide produced an ad ditive and safe reduction. However, for a clinically relevant evaluation they should have included a high-dose hydrochlorothiazide group and a highdose losartan group, or they should have used lower doses of both drugs in the combination regimen (i.e., to compare regimens with a more equal drug load). This would have challenged the merits of the combination of losartan and lowdose hydrochlorothiazide. Similarly, studies by Another frequently encountered manner in which drug load is neglected is the habit of not taking baseline medication into account. Onghena and van Houdenhove9 reviewed 39 placebo-controlled trials on antidepressant-induced analgesia for chronic nonmalignant pain and found that the use of other analgesic agents, ergotamine, or antirheumatic drugs was permitted in these trials. For example, in one of the reviewed articles, a study by Loldrup et al.,10 patients were allowed to have up to 30 mg oxazepam and up to 3 gm acetaminophen (INN, paracetamol) in addition to the study medication, without taking between-group differences of oxaze pam and acetaminophen into account. In an antihy pertension drug trial research, Avanzini et al.11 com pared the effects of four different drug regimens, but one regimen began with a considerably higher drug load than the others.
This problem is also important in add-on studies of antiepileptic drugs. The first trials to establish efficacy of a new antiepileptic drug are conducted by comparison of the new drug plus the existing, insuf ficiently effective, medication to placebo plus the CLINICAL PHARMACOLOGY & THERAPEUTICS VOLUME 62, NUMBER 6 Deckers et &L 593 existing medication. This is necessary because it is unethical to give only new antiepileptic drugs or placebo to patients with newly diagnosed epilepsy; thus the effects of the new compound are evaluated as though only the new drug were given. Plowever, we found that the total drug loads of baseline med ication of the active and placebo groups sometimes differ, and therefore it is unclear whether observed differences in toxicity are really the result of the new antiepileptic drug or whether they are related to drug load. 12 Polytherapy is being avoided in epilepsy treat ment because of the fear of adverse effects. This is based on studies published around 1980 in which patients who were switched back from polytherapy to monotherapy experienced a decrease in toxicity. However, the patients in these studies had not only a reduction in the number of antiepileptic drugs but also in drug load.12 Comparison of toxicity between patients receiving monotherapy and patients receiv ing polytherapy with equal drug loads has shown that toxicity does in fact not differ between these groups. 13 Although the concept of drug load is intuitively obvious, little has been published about a method to evaluate drug load in polytherapy. Such a method should be helpful in the planning and analysis of clinical trials and should enable deter mination of the role of drug load as a prognostic factor. In experimental settings, fractions of drug exposure are already used in the isobole method, This is the preferred method to detect synergy, zero interaction, or antagonism.14 The dosages of a drug combination (du, db ) are determined that have the same effect as certain dosages of the drugs alone (Da and Db). The equation for the zero interaction line for two agents is as follows; da/Da -I-db/Db ™ l.i4,us When the sum is less than one, the combination is judged to be supraaddilive; when the sum is more than one, the combi nation is judged to be infraadditive. The interac tion can thus be evaluated for the dosages used, irrespective of the dose-response curves of the individual drugs. We have developed a method to assess drug load that is analogous to the isobole method.
Methods
The unity of drug load can be defined as the average amount of drug needed to obtain the de sired effect in the general population. To approxi mate the unity drug load, the defined daily dose as 16 The World Health Organization Group determines and assigns the average maintenance dose of a drug for its main indication-the defined daily dose-for each individual drug by analysis of literature and drug registration data. The defined daily dose values of antiepileptic drugs are listed in Table I . The prescribed daily dose is the average prescribed dose in a particular population.
The prescribed daily dose/defined daily dose ratio can be used to calculate the drug load in treatment groups when the prescribed daily dose is used as the average dose of a drug taken in a certain treatment group. The method assumes that, thus normalized, the loads of several drugs in one regimen may be added.
For example, the defined daily dose of valproate sodium is 1500 mg and patients in group A taking 900 mg valproate would have a drug load of 900/ 1500, that is, 0.6 prescribed daily dose/defined daily dose. The defined daily dose of carbamazepine is 1000 mg and patients in group B taking 600 mg carbamazepine would have a drug load of 600/1000, which is also 0.6 prescribed daily dose/defined daily dose. Patients in group C taking 450 mg valproate and 300 mg carbamazepine would have an equal total drug load of 0,6 prescribed daily dose/deiined daily dose, which makes them eligible for compari son with patients of groups A and B. 
Results in epilepsy research
We have applied the described method of mea suring drug loads in a retrospective analysis of antiepileptic drug trials in which multiple drug regimens were used. In this review, toxicity was weakly but significantly correlated with drug load and not with the number of antiepileptic drugs.12 In one of the trials we analyzed, the authors assessed the neuro psychologic effects of a fixed dose of the antiepilep tic drug vigabatrin in an add-on placebo-controlled paradigm.17 No differences in neuropsychologie ef fects were found, and it was concluded that vigaba trin did not have a large effect on cognitive func tioning. However, analysis of the total drug loads of the two treatment groups revealed that, notwith standing the addition of vigabatrin to one group, drug loads in both treatment groups differed only slightly.12 This greatly decreases the likelihood of finding any difference in effect, if mechanisms are similar.
We have also used the prescribed daily dose/ defined daily dose ratio to start patients off with equal drug loads in both treatment groups of a clinical trial. In a recently initiated trial, we are comparing carbamazepine monotherapy to a com bination of carbamazepine and valproate sodium and all patients start with a drug load of 0.4 prescribed daily dose/defined daily dose, whether receiving monotherapy or duotherapy. This pre vents bias; for example, when one treatment group starts with a lower drug load it may take longer to get these patients into remission, al though the drugs may be equally effective. A lter natively, in a treatment group that starts off with a higher drug load, more patients may drop out fast because of adverse effects, while in fact the two regimens may be equally toxic when equal drug loads are used. Furthermore, the prescribed daily dose/defined daily dose ratio allows physicians participating in this trial to adjust the dose in terms of prescribed daily dose/defined daily dose, thus keeping physicians, patients, and investiga tors blinded.
In addition, prediction of the outcome of drug withdrawal after a reasonable symptom-free pe riod may benefit from the concept of drug load. Until now, the number of antiepileptic drugs has been deemed to be an important factor in deter mining the risk of seizure recurrence,18 The total drug load of the antiepileptic drug regimen may very well prove to be of more relevance in this respect.
D iscussion
Failure to evaluate drug load may complicate the evaluation of drug efficacy and toxicity, especially where combination therapy or fixed dosages are concerned. Equal drug loads should be verified at the start of treatment, as well as determined in the retrospective analysis of clinical trials. In our field antiepileptic drug treatment-neglecting drug load obscures the evaluation of new antiepileptic drugs and has also unjustly caused polytherapy to be blamed for increased toxicity.
With use of the prescribed daily dose/defined daily dose ratio, it is possible to evaluate whether an equal load of polytherapy may offer advantages compared with conventional monotherapy. Obvi ously, the inherent assumption when using this method is that the combination will exhibit additive activity. Deviations then will provide information about infraadditive or supraadditive activity. An other assumption is that the defined daily doses published by the World Health Organization are equipotent.
Conclusion
Drug load is a neglected factor in many trials in which drug combinations or fixed dosages are used. Taking drug load into account will clarify the inter pretation of the results of these trials. As a crude indicator the prescribed daily dose/defined daily dose ratio has already been useful to us in the assessment and planning of antiepileptic drug trials.
